The Global Pressure Vessel Market is expected to grow from USD 147,236.13 Million in 2018 to USD 192,362.13 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 3.89%
June 04, 2020 07:02 ET
|
ReportLinker
New York, June 04, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Pressure Vessel Market - Premium Insight, Competitive News Feed Analysis, Company Usability...
Mereo BioPharma Announces Completion of $70 Million Private Placement
June 04, 2020 07:00 ET
|
Mereo BioPharma Group plc
LONDON and REDWOOD CITY, Calif., June 04, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) today announces the completion of a $70 million (£56 million) private placement...
Nasdaq Ventures Invests in Automated Financial Crime Investigations Firm Caspian
June 04, 2020 07:00 ET
|
Nasdaq, Inc.
NEW YORK, June 04, 2020 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) announced today that its investment arm, Nasdaq Ventures, has taken a minority stake in the UK-based financial crime investigation...
Esperion Announces Commercial Availability of NEXLIZET™ (bempedoic acid and ezetimibe) Tablets and Ushers in New Era of Oral Combination Medicine for LDL-Cholesterol Lowering
June 04, 2020 07:00 ET
|
Esperion Therapeutics, Inc.
– First-Ever Non-Statin Combination Medicine, Providing 38 Percent Mean LDL-C Lowering – – Esperion Aims to Set New Industry Standard by Pricing NEXLIZET for Patient Affordability and Access with...
CareDx to Participate at the Goldman Sachs Global Healthcare Conference
June 04, 2020 07:00 ET
|
CareDx, Inc.
SOUTH SAN FRANCISCO, Calif., June 04, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of...
Prevail Therapeutics Appoints Kira Schwartz, J.D., as General Counsel
June 04, 2020 07:00 ET
|
Prevail Therapeutics
NEW YORK, June 04, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
Microbix Announces Quality Products Distribution Agreement
June 04, 2020 07:00 ET
|
Microbix Biosystems Inc.
MISSISSAUGA, Ontario, June 04, 2020 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces the appointment of Alpha-Tec...
Anavex Life Sciences Receives Regulatory Approval from Health Canada and UK MHRA Expanding Phase 2b/3 ANAVEX®2-73 (blarcamesine) into Multinational Clinical Trial for Alzheimer’s Disease
June 04, 2020 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, June 04, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Axsome Therapeutics to Present at Upcoming Investor Conferences
June 04, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, June 04, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Amicus Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
June 04, 2020 07:00 ET
|
Amicus Therapeutics, Inc.
CRANBURY, N.J., June 04, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a fireside chat...
- May 03, 2024 19:15 ET GDRX Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Against GoodRx Holdings, Inc.
- May 03, 2024 19:13 ET ADSK Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Against Autodesk, Inc.